These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 1489940)

  • 1. Simultaneous modelling of mexiletine and hydroxy-methyl-mexiletine data after single- and multiple-dose administration of a sustained-release mexiletine formulation.
    Bruno R; Santoni Y; Iliadis A; Djiane P; Serradimigni A; Cano JP
    Biopharm Drug Dispos; 1992 Oct; 13(7):481-93. PubMed ID: 1489940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of mexiletine.
    Labbé L; Turgeon J
    Clin Pharmacokinet; 1999 Nov; 37(5):361-84. PubMed ID: 10589372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of mexiletine and its metabolites, hydroxymethylmexiletine and p-hydroxymexiletine, after single oral administration in healthy subjects.
    Paczkowski D; Sadowski Z; Filipek M; Koliński P
    Pol J Pharmacol Pharm; 1990; 42(4):365-75. PubMed ID: 2097598
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mexiletine in acute myocardial infarction. Simulation of a theoretical protocol and validation in six patients.
    Lévy-Prades R; Philip F; Danays T; Serradimigni A; Cano JP
    Arzneimittelforschung; 1989 Aug; 39(8):903-8. PubMed ID: 2818679
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the plasma concentrations and efficacy of mexiletine and of a slow-release preparation of mexiletine in patients admitted to a coronary care unit.
    Boyle DM; Barber JM; Chapman C; Khalid I; Kinney CD; McIlmoyle EL; Salathia K; Shanks RG
    J Cardiovasc Pharmacol; 1982; 4(2):174-9. PubMed ID: 6175798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptation of the dose of mexiletine according to pharmacokinetic data.
    Bogaert M
    Acta Cardiol Suppl; 1980; (25):67-73. PubMed ID: 6966454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The pharmacokinetics and bioavailability of a new mexiletine preparation in healthy volunteers].
    Hutt V; Pabst G; Salama Z; Kappler J; Jaeger H
    Arzneimittelforschung; 1995 Mar; 45(3):254-7. PubMed ID: 7741779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A study to compare the efficacy, plasma concentration profile and tolerability of conventional mexiletine and slow-release mexiletine.
    Upward JW; Holt DW; Jackson G
    Eur Heart J; 1984 Mar; 5(3):247-52. PubMed ID: 6723694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of age on the pharmacokinetics of mexiletine.
    el Allaf D; Carlier J; Dressé A
    Int J Clin Pharmacol Res; 1986; 6(4):303-7. PubMed ID: 3759283
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mexiletine effects on theophylline disposition.
    Hurwitz A; Vacek JL; Botteron GW; Sztern MI; Hughes EM; Jayaraj A
    Clin Pharmacol Ther; 1991 Sep; 50(3):299-307. PubMed ID: 1914365
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dependency of salivary excretion of mexiletine on the plasma concentration in rats.
    Nagasako S; Iwamoto K; Hayashibara M; Katagiri Y
    J Pharm Pharmacol; 1993 Feb; 45(2):154-6. PubMed ID: 8095536
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics of mexiletine in the elderly.
    Grech-Bélanger O; Barbeau G; Kishka P; Fiset C; LeBoeuf E; Blouin M
    J Clin Pharmacol; 1989 Apr; 29(4):311-5. PubMed ID: 2723119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic interaction between mexiletine and propafenone in human beings.
    Labbé L; O'Hara G; Lefebvre M; Lessard E; Gilbert M; Adedoyin A; Champagne J; Hamelin B; Turgeon J
    Clin Pharmacol Ther; 2000 Jul; 68(1):44-57. PubMed ID: 10945315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.
    Abolfathi Z; Fiset C; Gilbert M; Moerike K; Bélanger PM; Turgeon J
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1196-201. PubMed ID: 8371133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stereoselective disposition of the antiarrhythmic agent mexiletine during the concomitant administration of caffeine.
    Labbé L; Abolfathi Z; Robitaille NM; St-Maurice F; Gilbert M; Turgeon J
    Ther Drug Monit; 1999 Apr; 21(2):191-9. PubMed ID: 10217339
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Signal-averaged ECG in prediction of the short-term suppression of ventricular premature beats by Mexiletine.
    Zaliunas R; Zabiela P; Slapikas R; Vainoras A; Pentiokiniene D; Levisauskiene R; Bechtold H; Meyer U
    Int J Cardiol; 1994 Oct; 46(3):243-54. PubMed ID: 7529214
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The pharmacokinetics of the enantiomers of mexiletine in humans.
    Igwemezie L; Kerr CR; McErlane KM
    Xenobiotica; 1989 Jun; 19(6):677-82. PubMed ID: 2763576
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The effect of mexiletine on theophylline pharmacokinetics in patients with bronchial asthma].
    Inafuku M; Suzuki T; Ohtsu F; Hariya Y; Nagasawa K; Yoshioka Y; Nakahara Y; Hayakawa H
    J Cardiol; 1992; 22(1):227-33. PubMed ID: 1284909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of ciprofloxacin on the stereoselective disposition of mexiletine in man.
    Labbé L; Robitaille NM; Lefez C; Potvin D; Gilbert M; O'Hara G; Turgeon J
    Ther Drug Monit; 2004 Oct; 26(5):492-8. PubMed ID: 15385831
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and the antiarrhythmic effect of mexiletine in patients with chronic ventricular arrhythmias.
    Ohashi K; Ebihara A; Hashimoto T; Hosoda S; Kondo K; Oka T
    Arzneimittelforschung; 1984; 34(4):503-7. PubMed ID: 6540110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.